Treatment decisions, clinical outcomes, and pharmacoeconomics in the treatment of patients with EGFR mutated stage III/IV NSCLC in Germany: an observational study.

6. Februar 2018

Schuette, W., Schirmacher, P., Eberhardt, W.E.E., Dietel, M., Zirrgiebel, U., Muehlenhoff, L., Thomas, M., 2018.

BMC Cancer 18, 135. doi:10.1186/s12885-018-4032-3

Abstract